利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.016 秒)

    NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION
    4.
    发明授权
    NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION 有权
    NEW胍衍生物作为ZELLADHÄSIONHEMMER

    公开(公告)号：EP1313737B1

    公开(公告)日：2009-06-03

    申请号：EP01956555.5

    申请日：2001-07-23

    申请人： Aventis Pharma Deutschland GmbH ,  Genentech, Inc.

    发明人： PEYMAN, Anushirwan ,  WILL, David ,  GADEK, Thomas, R. ,  McDOWELL, Robert ,  GOURVEST, Jean-François ,  RUXER, Jean-Marie ,  KNOLLE, Jochen

    IPC分类号： C07D473/34 ,  C07D487/04 ,  A61K31/52 ,  A61P19/10

    CPC分类号： C07D473/00 ,  C07D487/04

    摘要： The present invention relates to acylguanidino derivatives of formula (I), in which R?1, R2, R3¿, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical compositions comprising them.

    NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
    6.
    发明公开
    NAPHTHYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM 有权
    萘啶衍生物，PROCESS FOR THEIR，其应用和YOU药物组合物含

    公开(公告)号：EP1210348A1

    公开(公告)日：2002-06-05

    申请号：EP00945825.8

    申请日：2000-06-26

    申请人： Aventis Pharma Deutschland GmbH ,  Genentech, Inc.

    发明人： PEYMAN, Anuschirvan ,  SCHEUNEMANN, Karl-Heinz ,  GADEK, Thomas, R. ,  GOURVEST, Jean-François ,  RUXER, Jean-Marie

    IPC分类号： C07D473/34 ,  A61K31/52

    CPC分类号： C07D473/34

    摘要： The present invention relates to compounds of formula (I), in which B, G, Z, X, Y, r, s and t have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

    SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION
    7.
    发明公开
    SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION 有权
    取代的嘌呤衍生物作为细胞ADHÄSIONHEMMER

    公开(公告)号：EP1196416A1

    公开(公告)日：2002-04-17

    申请号：EP00940406.2

    申请日：2000-06-26

    申请人： Aventis Pharma Deutschland GmbH ,  Genentech Inc.

    发明人： PEYMAN, Anuschirwan ,  KNOLLE, Jochen ,  GADEK, Thomas, R. ,  GOURVEST, Jean-François ,  RUXER, Jean-Marie

    IPC分类号： C07D473/34 ,  A61K31/52

    CPC分类号： C07D473/34

    摘要： The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.